Somebody deciding what to do about their weight is choosing between four or five approaches. Almost every source they will read is selling one of them — including, to be plain about it, the market this site covers. This review is not, and its ordering is not the one a website would produce.
What it covers
A narrative synthesis of real-world evidence — adherence, persistence, discontinuation, tolerability, access and patient satisfaction — across intensive lifestyle programs, pharmacotherapy including the incretin drugs, metabolic bariatric surgery, and endoscopic procedures, searched through July 2026. [1] Randomized trials are used to give context to what happens in practice rather than to stand in for it.
Where the drugs actually land
Incretin-based therapies produce substantial weight loss in trials and relatively smaller effectiveness in practice. The review names five reasons: people not starting at all, incomplete dose escalation, gastrointestinal side effects, treatment interruptions, and financial or insurance barriers.
That list is worth reading slowly, because four of the five have nothing to do with price. This site’s own coverage keeps arriving at the same place — in a clinic program where the drug was free, median persistence was still under eleven months. A cheaper seller solves one of five problems.
The other options, briefly
Intensive lifestyle programs generally achieve about 5% weight loss, with attrition during and regain after. Older weight medications show poor persistence driven by neurologic, psychiatric or gastrointestinal intolerance, despite some of them costing far less.
Endoscopic sleeve gastroplasty produces moderate, durable weight loss with low rates of serious adverse events. Intragastric balloons are more limited — by intolerance, by the need for reintervention, and by regain after removal.
What this changes about a purchase
It reframes the question from “which seller” to “which treatment”, and most people arrive at this market having skipped that step. A telehealth intake form is not a place where surgery gets discussed, and a price comparison cannot tell you that the most durable option in the literature is one you have not been offered.
None of which makes buying a GLP-1 wrong. It makes it a choice among several, with real trade-offs on cost, durability, invasiveness and access. Once that choice is made, the arithmetic this site does applies — what a GLP-1 actually costs and what six months of it comes to are the right questions at that point, and the wrong ones before it.
The review’s own conclusion is that real-world effectiveness is determined not only by biological efficacy but by tolerability, adherence, access and sustained support. Three of those four are things a website cannot supply, which is worth knowing before weighing the money against the outcome.